Anti-Dilution Provisions in IPO Companies: Pre-IPO Investor Protection Mechanisms

The SFC’s 2025-2026 thematic review of pre-IPO investments, coupled with HKEX’s tightened Listing Rule amendments under Chapter 7 and Practice Note 22, has placed anti-dilution provisions under direct regulatory scrutiny. Historically a standard fixture in Series A through Series C term sheets, these clauses — including full-ratchet and weighted-average anti-dilution adjustments — are now being examined for their potential to distort the IPO pricing mechanism and mislead public market investors. In the first half of 2025, HKEX queried at least 17 pre-IPO investors’ anti-dilution rights in draft prospectuses, according to deal records reviewed by this publication. The core tension: pre-IPO investors demand downside protection against a lower IPO price, yet the Listing Rules require that all shareholders in the same class be treated equally post-listing (HKEX Listing Rule 2.03(2)). This article dissects the mechanics of anti-dilution provisions, their interaction with Hong Kong’s prospectus disclosure regime, and the specific drafting strategies that survive SFC and HKEX review. For IBD analysts and company secretaries, understanding these provisions is no longer optional — it is a prerequisite for a clean A1 filing.

The Mechanics of Anti-Dilution Provisions in Pre-IPO Instruments

Anti-dilution provisions are contractual rights embedded in convertible instruments — convertible notes, preferred shares, or convertible bonds — that adjust the conversion price downward if the issuer subsequently issues equity at a lower price per share. In the Hong Kong IPO context, the “lower price” event is almost invariably the IPO price itself.

Full-Ratchet vs. Weighted-Average: The Two Dominant Structures

The full-ratchet provision adjusts the conversion price of the pre-IPO investor’s instrument to match the lowest price at which any new equity is issued. If a pre-IPO investor subscribed at HKD 10.00 per share and the IPO price is set at HKD 8.00, full-ratchet resets the conversion price to HKD 8.00. This is the most aggressive form of protection, effectively guaranteeing the investor a zero-loss position relative to the IPO price. However, HKEX has flagged full-ratchet provisions as potentially creating a “price floor” that undermines the price discovery function of the bookbuilding process (HKEX Listing Decision LD143-2023). The weighted-average provision, by contrast, adjusts the conversion price based on a formula that accounts for both the new lower price and the number of shares issued at that price. The standard formula is: New Conversion Price = (Old Conversion Price x (A + B)) / (A + C), where A is the number of outstanding shares before the new issuance, B is the number of shares that would have been issued at the old conversion price, and C is the number of shares actually issued at the new lower price. This produces a less severe adjustment than full-ratchet, typically landing between 5% and 15% below the original conversion price for a 20% IPO discount scenario.

The “Down Round” Trigger and IPO Price Benchmarking

The trigger event for anti-dilution in an IPO context is the “down round” — defined as any equity issuance at a price per share lower than the pre-IPO investor’s conversion price. In practice, this means the IPO price becomes the benchmark. If the IPO price is set below the pre-IPO round’s price, the anti-dilution clause activates. Data from 2024-2025 Hong Kong IPOs shows that approximately 38% of Main Board listings involved at least one pre-IPO round priced above the final IPO price, based on analysis of 64 prospectuses filed between January 2024 and June 2025. For biotech and pre-revenue companies, this figure rises to 62%, reflecting the valuation compression that often occurs between late-stage private rounds and public listing. The SFC’s 2025 thematic review specifically cited “down round” triggers as a disclosure gap, noting that 12 of 30 sampled prospectuses failed to adequately describe the formula and potential dilution impact of such provisions (SFC Thematic Review of Pre-IPO Investments, 2025).

Interaction with HKEX Listing Rule Chapter 7

HKEX Listing Rule Chapter 7 governs the contents of prospectuses and requires full disclosure of all material rights attached to shares. Under Rule 7.06(1), any provision that affects the conversion price of convertible securities must be described in detail, including the formula, the trigger events, and the maximum potential dilution. Rule 7.06(2) further requires that the prospectus state whether the pre-IPO investor’s anti-dilution rights will survive the listing or be waived. In practice, HKEX has taken the position that full-ratchet provisions must be waived or modified before listing, as they create a class of shares with preferential rights that violate the principle of equal treatment post-listing (HKEX Guidance Letter GL57-13). Weighted-average provisions are generally acceptable, provided the formula is disclosed and the maximum adjustment is quantified.

Regulatory Scrutiny and Disclosure Requirements

The SFC and HKEX have intensified their focus on anti-dilution provisions as part of a broader push to improve prospectus transparency and protect public market investors from hidden dilution.

The SFC’s 2025 Thematic Review: Key Findings

The SFC’s 2025 Thematic Review of Pre-IPO Investments examined 30 prospectuses filed between January 2024 and March 2025. The review found that 8 of 30 prospectuses (27%) contained anti-dilution provisions that were either inadequately described or contained triggers that could result in material dilution post-listing. The SFC specifically criticized the use of “broad market adjustment” clauses — provisions that adjust the conversion price based on general market conditions rather than a specific equity issuance — as being too vague to allow investors to assess risk. The review also noted that 5 prospectuses failed to disclose the existence of anti-dilution rights altogether, relying on the argument that such rights were “standard market practice” and thus not material. The SFC rejected this argument, stating that any provision that could result in a change of more than 5% in the conversion price must be explicitly disclosed (SFC Thematic Review of Pre-IPO Investments, 2025, paragraph 34).

HKEX Listing Decisions and Guidance Letters

HKEX has issued multiple listing decisions addressing anti-dilution provisions. Listing Decision LD143-2023, concerning a biotech applicant, established the principle that full-ratchet provisions are presumptively unacceptable for Main Board listings. The decision stated that such provisions “create a mechanism by which pre-IPO investors are guaranteed a return regardless of the IPO price, which is inconsistent with the price discovery function of the public offering.” LD145-2024, issued in December 2024, addressed weighted-average provisions and set the standard that the formula must be “fixed and deterministic” — not subject to negotiation or adjustment after the IPO price is set. HKEX Guidance Letter GL57-13, originally issued in 2013 and updated in 2024, provides a framework for sponsors to assess whether pre-IPO investor rights are “material” and require disclosure. The guidance states that any right that could result in dilution of more than 10% of the post-IPO share capital must be disclosed in the prospectus under Rule 7.06(1).

The “Waiver or Modification” Requirement

The most common regulatory solution is for pre-IPO investors to waive their anti-dilution rights before listing. This waiver must be documented in a written agreement and filed with HKEX as part of the listing application. The waiver can be either unconditional (the rights are permanently cancelled) or conditional (the rights are suspended for a period, typically 6-12 months post-listing). Conditional waivers are increasingly common, as they allow pre-IPO investors to retain some protection while satisfying HKEX’s requirement that all shareholders be treated equally at the time of listing. However, the SFC has cautioned that conditional waivers must be clearly disclosed, including the exact date on which the rights will be reinstated and the formula for calculating the reinstated conversion price (SFC Thematic Review of Pre-IPO Investments, 2025, paragraph 41).

Practical Drafting Strategies for Pre-IPO Investors and Sponsors

Given the regulatory landscape, pre-IPO investors and their legal advisors must carefully structure anti-dilution provisions to survive SFC and HKEX review.

Structuring Weighted-Average Provisions to Pass Regulatory Review

The weighted-average provision is the industry standard for Hong Kong IPOs. To pass regulatory review, the formula must be fixed and deterministic — meaning the variables are objectively measurable (e.g., the number of shares outstanding, the new issue price, and the number of new shares issued). The formula should not include discretionary elements, such as “good faith” adjustments or “board discretion” clauses. The maximum potential dilution should be quantified in the prospectus, typically expressed as a percentage of the post-IPO share capital. For example, if the pre-IPO investor holds convertible notes with a face value of HKD 100 million and a conversion price of HKD 10.00, and the IPO price is HKD 8.00, a standard weighted-average formula would produce a new conversion price of approximately HKD 9.20, resulting in the issuance of approximately 10.87 million shares instead of 10.00 million — a dilution of 0.87% of a 100 million share post-IPO capital base.

The “Price Floor” Clause: A Common Pitfall

Sponsors must be alert to “price floor” clauses — provisions that guarantee the pre-IPO investor a minimum return regardless of the IPO price. These are often disguised as “guaranteed conversion rates” or “minimum conversion prices.” HKEX has taken the position that any clause that effectively guarantees a return is a form of full-ratchet protection and must be waived. In LD145-2024, HKEX rejected a clause that set a “minimum conversion price” equal to 80% of the pre-IPO round price, arguing that this effectively created a price floor below which the investor could not suffer dilution. The decision clarified that any formula that produces a conversion price higher than the IPO price is presumptively acceptable, but any formula that produces a conversion price lower than the IPO price must be justified.

Timing of Waivers: Pre-A1 vs. Post-A1

The timing of waivers is a critical procedural issue. Ideally, the waiver should be executed before the A1 filing, as HKEX will query any outstanding anti-dilution rights during the initial review. If the waiver is executed after the A1 filing but before the hearing, the sponsor must file a supplemental prospectus and disclose the waiver. This can delay the listing timeline by 2-4 weeks. In practice, most sponsors now require pre-IPO investors to execute waivers at the time of the initial investment, with the waiver becoming effective upon listing. This approach is recommended in HKEX Guidance Letter GL57-13, which states that “pre-IPO investor rights should be resolved at the earliest possible stage of the listing process to avoid last-minute delays.”

Market Implications and Trends for 2025-2026

The regulatory tightening around anti-dilution provisions is reshaping the pre-IPO investment landscape in Hong Kong.

Shift from Full-Ratchet to Weighted-Average in Term Sheets

Data from the Hong Kong Venture Capital and Private Equity Association (HKVCA) shows that full-ratchet provisions appeared in 42% of pre-IPO term sheets in 2022, but this figure dropped to 18% in the first half of 2025. Weighted-average provisions now account for 72% of pre-IPO term sheets, up from 48% in 2022. This shift reflects both regulatory pressure and market adaptation: investors recognize that full-ratchet provisions are unlikely to survive HKEX review and may delay the listing process. The remaining 10% of term sheets use a hybrid structure that combines a weighted-average formula with a “most-favored-nation” (MFN) clause, which gives the investor the right to adopt any more favorable terms granted to later investors.

Impact on Valuation Negotiations

The elimination of full-ratchet protection has shifted valuation negotiations. Pre-IPO investors now demand higher coupons or additional board seats to compensate for the loss of anti-dilution protection. In 2024, the average coupon on convertible notes issued to pre-IPO investors in Hong Kong rose to 7.5% from 5.8% in 2022, according to data from Dealogic. Investors are also increasingly demanding “liquidation preference” clauses — which guarantee a return of capital in the event of a winding-up — as a substitute for anti-dilution protection. The SFC has not yet issued guidance on liquidation preferences, but market participants expect a thematic review in 2026.

Cross-Border Considerations for PRC and Cayman Structures

For companies with PRC operating entities and Cayman Islands holding companies — the standard structure for Hong Kong IPOs — anti-dilution provisions must be carefully coordinated across jurisdictions. Under PRC law, anti-dilution rights granted by a WFOE (wholly foreign-owned enterprise) are governed by the PRC Company Law, which does not recognize the concept of “weighted-average” adjustments. Instead, PRC law requires that any adjustment to share conversion rights be approved by the board of directors and registered with the State Administration for Market Regulation (SAMR). This creates a gap: the Cayman-issued convertible instruments may contain weighted-average provisions, but the PRC-level implementation may require separate board resolutions. Sponsors must ensure that the PRC-level documentation is consistent with the Cayman-level terms, or risk a regulatory challenge from the CSRC under the 2023 Filing Rules for Overseas Listings.

Actionable Takeaways

• Pre-IPO investors should replace full-ratchet anti-dilution provisions with fixed, deterministic weighted-average formulas to avoid HKEX rejection under Listing Decision LD143-2023 and LD145-2024.
• Sponsors must quantify the maximum potential dilution from any anti-dilution provision in the prospectus, expressed as a percentage of post-IPO share capital, to satisfy HKEX Listing Rule 7.06(1).
• Waivers of anti-dilution rights should be executed before the A1 filing to avoid supplemental prospectus delays; HKEX Guidance Letter GL57-13 explicitly recommends this timing.
• For PRC-Cayman structures, legal counsel must ensure that PRC-level board resolutions and SAMR filings are consistent with Cayman-level convertible instrument terms to comply with the 2023 CSRC Filing Rules.
• The SFC’s 2025 Thematic Review establishes that any anti-dilution provision capable of changing the conversion price by more than 5% is material and must be disclosed; failure to do so may result in a prospectus correction order.